hydralazine and rrx-001

hydralazine has been researched along with rrx-001 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K	1

Reviews

1 review(s) available for hydralazine and rrx-001

Article	Year
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid	2016

Article

Year

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid

2016